Case-control estimation of the impact of oncolytic adenovirus on the survival of patients with refractory solid tumors

Molecular Therapy

Volumn 23, Issue 2, 2015, Pages 321-329

  Kanerva, Anna ^a,b   Koski, Anniina ^a   Liikanen, Ilkka ^a   Oksanen, Minna ^a   Joensuu, Timo ^c   Hemminki, Otto ^a   Palmgren, Juni ^d   Hemminki, Kari ^e,f   Hemminki, Akseli ^a,c,g  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c Docrates Clinic   (Finland)

^d KAROLINSKA INSTITUTE   (Sweden)

^e GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^f LUND UNIVERSITY   (Sweden)

^g TILT Biotherapeutics Ltd   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

ONCOLYTIC ADENOVIRUS; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; ONCOLYTIC VIRUS;

ADOLESCENT; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CASE CONTROL STUDY; CHILD; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HEAD AND NECK CANCER; HUMAN; INTESTINE CANCER; LIVER CANCER; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MELANOMA; MESOTHELIOMA; NEUROENDOCRINE TUMOR; ONCOLYTIC VIROTHERAPY; OVARY CANCER; OVERALL SURVIVAL; PANCREAS CANCER; PROSTATE CANCER; SARCOMA; SOLID TUMOR; STOMACH CANCER; SURVIVAL TIME; TREATMENT OUTCOME; URINARY TRACT CANCER; UTERUS CANCER; VERY ELDERLY; ADENOVIRIDAE; ADMINISTRATION AND DOSAGE; GENE THERAPY; GENE VECTOR; GENETICS; KAPLAN MEIER METHOD; MIDDLE AGED; MORTALITY; NEOPLASMS; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; YOUNG ADULT;

ADENOVIRIDAE; REPLICATION COMPETENT VIRUSES;

ADENOVIRIDAE; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CASE-CONTROL STUDIES; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC THERAPY; GENETIC VECTORS; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROPORTIONAL HAZARDS MODELS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84922262706     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2014.218     Document Type: Article

References (34)

1. Pesonen S, Helin H, Nokisalmi P, Escutenaire S, Ribacka C, Sarkioja M., et al. (2010). Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol 49: 117-119
2. Pesonen S, Nokisalmi P, Escutenaire S, Särkioja M, Raki M, Cerullo V., et al. (2010). Prolonged systemic circulation of chimeric oncolytic adenovirus Ad5/3-Cox2L-D24 in patients with metastatic and refractory solid tumors. Gene Ther 17: 892-904
3. Cerullo V, Pesonen S, Diaconu I, Escutenaire S, Arstila PT, Ugolini M., et al. (2010). Oncolytic adenovirus coding for granulocyte macrophage colonystimulating factor induces antitumoral immunity in cancer patients. Cancer Res 70: 4297-4309
4. Nokisalmi P, Pesonen S, Escutenaire S, Särkioja M, Raki M, Cerullo V., et al. (2010). Oncolytic adenovirus ICOVIR-7 in patients with advanced and refractory solid tumors. Clin Cancer Res 16: 3035-3043
5. Koski A, Kangasniemi L, Escutenaire S, Pesonen S, Cerullo V, Diaconu I., et al. (2010). Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol Ther 18: 1874-1884
6. Rajecki M, Raki M, Escutenaire S, Pesonen S, Cerullo V, Helminen A., et al. (2011). Safety of glucocorticoids in cancer patients treated with oncolytic adenoviruses. Mol Pharm 8: 93-103
7. Cerullo V, Diaconu I, Kangasniemi L, Rajecki M, Escutenaire S, Koski A., et al. (2011). Immunological effects of low-dose cyclophosphamide in cancer patients treated with oncolytic adenovirus. Mol Ther 19: 1737-1746
8. Pesonen S, Diaconu I, Cerullo V, Escutenaire S, Raki M, Kangasniemi L., et al. (2012). Integrin targeted oncolytic adenoviruses Ad5-D24-RGD and Ad5-RGD-D24- GMCSF for treatment of patients with advanced chemotherapy refractory solid tumors. Int J Cancer 130: 1937-1947
9. Koski A, Raki M, Nokisalmi P, Liikanen I, Kangasniemi L, Joensuu T., et al. (2012). Verapamil results in increased blood levels of oncolytic adenovirus in treatment of patients with advanced cancer. Mol Ther 20: 221-229
10. Pesonen S, Diaconu I, Kangasniemi L, Ranki T, Kanerva A, Pesonen SK., et al. (2012). Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res 72: 1621-1631
11. Hemminki O, Diaconu I, Cerullo V, Pesonen SK, Kanerva A, Joensuu T., et al. (2012). Ad3-hTERT-E1A, a fully serotype 3 oncolytic adenovirus in patients with chemotherapy refractory cancer. Mol Ther 20: 1821-1830
12. Kanerva A, Nokisalmi P, Diaconu I, Koski A, Cerullo V, Liikanen I., et al. (2013). Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res 19: 2734-2744
13. Liikanen I, Ahtiainen L, Hirvinen ML, Bramante S, Cerullo V, Nokisalmi P., et al. (2013). Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol Ther 21: 1212-1223
14. Bramante S, Koski A, Kipar A, Diaconu I, Liikanen I, Hemminki O., et al. (2014). Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer 135: 720-730
15. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363: 711-723
16. Kantoff PW, Higano CS, Shore ND, Berger ER, Small EJ, Penson DF., et al.; IMPACT Study Investigators. (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med 363: 411-422
17. Markman M, Webster K, Zanotti K, Peterson G, Kulp B and Belinson J. (2004). Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trials. Gynecol Oncol 93: 699-701
18. Peled Y, Levavi H, Krissi H, Weill Y, Sabah G and Eitan R. (2013). The use of Fluorouracil (5-FU) and leucovorin in women with heavily pretreated advanced ovarian carcinoma. Am J Clin Oncol 36: 472-474
19. Kaufman HL, Andtbacka RHI Collichio FA, Amatruda T, Senzer NN, Chesney J., et al. (2014). Primary overall survival (OS) from OPTiM a randomized phase III trial of talimogene laherparepvec (T-VEC) versus subcutaneous (SC) granulocytemacrophage colony-stimulating factor (GM-CSF) for the treatment (tx) of unresected stage IIIB/C and IV melanoma. ASCO Meeting Abstracts. J Clin Oncol 32: 9008a.
20. UKCCCR Elderly Cancer Patients in Clinical Trials Working Group. (2000). Position paper by the UKCCCR elderly cancer patients in clinical trials working group. Br J Cancer 82: 1-3
21. Nixon AJ, Neuberg D, Hayes DF, Gelman R, Connolly JL, Schnitt S., et al. (1994). Relationship of patient age to pathologic features of the tumor and prognosis for patients with stage I or II breast cancer. J Clin Oncol 12: 888-894
22. Xiong Q, Valero V, Kau V, Kau SW, Taylor S, Smith TL., et al. (2001). Female patients with breast carcinoma age 30 years and younger have a poor prognosis: the M.D. Anderson Cancer Center experience. Cancer 92: 2523-2528
23. Dranoff G. (2002). GM-CSF-based cancer vaccines. Immunol Rev 188: 147-154
24. Koski A, Ahtinen H, Liljenback H, Roivainen A, Koskela A, Oksanen M., et al. (2013). [(18)F]-fluorodeoxyglucose positron emission tomography and computed tomography in response evaluation of oncolytic adenovirus treatments of patients with advanced cancer. Hum Gene Ther 24: 1029-1041
25. Kohanbash G, McKaveney K, Sakaki M, Ueda R, Mintz AH, Amankulor N., et al. (2013). GM-CSF promotes the immunosuppressive activity of gliomainfiltrating myeloid cells through interleukin-4 receptor-a. Cancer Res 73: 6413-6423
26. Bayne LJ, Beatty GL, Jhala N, Clark CE, Rhim AD, Stanger BZ., et al. (2012). Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and t cell immunity in pancreatic cancer. Cancer Cell 21: 822-835
27. Pylayeva-Gupta Y, Lee KE, Hajdu CH, Miller G and Bar-Sagi D. (2012). Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. Cancer Cell 21: 836-847
28. Umansky V and Sevko A. (2013). Tumor microenvironment and myeloid-derived suppressor cells. Cancer Microenviron 6: 169-177
29. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr and Kinzler KW. (2013). Cancer genome landscapes. Science 339: 1546-1558
30. Whiteside TL. (2013). Immune modulation of T-cell and NK (natural killer) cell activities by TEXs (tumour-derived exosomes). Biochem Soc Trans 41: 245-251
31. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F., et al. (2005). Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA 102: 18538-18543
32. Ayyoub M, Pignon P, Classe JM, Odunsi K and Valmori D. (2013). CD4+ T effectors specific for the tumor antigen NY-ESO-1 are highly enriched at ovarian cancer sites and coexist with but are distinct from tumor-associated Treg. Cancer Immunol Res 1: 303-308
33. Melichar B and Freedman RS. (2002). Immunology of the peritoneal cavity: relevance for host-tumor relation. Int J Gynecol Cancer 12: 3-17
34. Wertel I, Nowicka A, Rogala E and Kotarski J. (2011). Peritoneal immune system in patients with advance epithelial ovarian cancer. Int Rev Immunol 30: 87-101